07:00 , Jun 18, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD55

Infectious disease INDICATION: Malaria In vitro studies suggest inhibiting CD55 on red blood cells (RBCs) could help treat malaria. In vitro, transduction of hematopoietic progenitor cells with an shRNA library, followed by cell maturation to erythroblast stage...
07:00 , Aug 16, 2010 |  BC Week In Review  |  Company News

Scancell, Cancer Research U.K. deal

Scancell received a worldwide license from Cancer Research Technology Ltd., the commercialization and development arm of Cancer Research U.K., to use 105AD7 to develop new ImmunoBody vaccines for all immunotherapy indications. The human mAb...
07:00 , Jun 17, 2010 |  BC Innovations  |  Distillery Techniques

Technology: Drug delivery

Approach Summary Licensing status Publication and contact information Drug delivery Adenovirus capsids displaying human CD55 as safe gene transfer vectors In vitro and mouse studies suggest that CD55-expressing adenovirus...
08:00 , Feb 8, 2010 |  BC Week In Review  |  Company News

CSL, Patrys deal

Patrys granted CSL an exclusive, worldwide license to develop products based on two undisclosed antibodies and an exclusive option to select up to two additional early-stage antibodies. Patrys will receive an undisclosed upfront fee and...
07:00 , Oct 12, 2009 |  BC Week In Review  |  Company News

Debiopharm S.A., Patrys deal

Patrys acquired exclusive, worldwide rights to SC1 ( SC-1) from Debiopharm's Debiovision Inc. unit. Patrys renamed the compound PAT-SC1. The human IgM mAb targeting an isoform of CD55 was originally developed by ...
07:00 , Jul 2, 2007 |  BC Week In Review  |  Company News

Oxford BioMedica, Viragen, Roslin Institute deal

VRA will halt further development of its OVA avian transgenic technology for manufacturing therapeutic proteins and terminate related research and license agreements with OXB and the institute. OVA uses OXB's LentiVector gene delivery technology, which...
07:00 , May 29, 2006 |  BioCentury  |  Product Development

Cancer vaccines in development

Cancer vaccines in development Company Product Description Indication Status Avax/Pro Vaccine/Australian Vaccine Tech M-Vax Autologous haptenized tumor cell vaccine Stage III and IV melanoma Compassionate use in France, Spain and Belgium; Ph I/II in U.S....
07:00 , May 16, 2005 |  BC Week In Review  |  Company News

Viragen, Cancer Research Technology Limited deal

VRA exercised an option to acquire exclusive worldwide development and marketing rights to Cancer Research's anti- CD55 antibody, which is in preclinical testing to treat cancer. Viragen Inc. (VRA), Plantation, Fla.   Cancer Research Technology Limited,...
07:00 , Apr 25, 2005 |  BC Week In Review  |  Clinical News

Onyvax-105: Phase I/II data

Data from a U.K. Phase I/II trial in 31 patients showed that 2 patients remain disease free 5.8 and 6.5 years after their original diagnosis. About 71% of patients showed measurable T cell responses when...
08:00 , Mar 21, 2005 |  BC Week In Review  |  Clinical News

Viragen preclinical data

In an in vitro study, anti-CD55 antibody in combination with Rituxan significantly increased the destruction of cancer cells compared to Rituxan alone. Rituxan rituximab is marketed by Biogen Idec Inc. (BIIB, Cambridge, Mass.), Genentech...